Elicera Therapeutics AB (publ) (STO:ELIC)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.74
-0.76 (-11.69%)
Mar 9, 2026, 5:29 PM CET
143.22%
Market Cap 315.48M
Revenue (ttm) 10.86M
Net Income (ttm) -17.41M
Shares Out 48.54M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE 4.41
Dividend n/a
Ex-Dividend Date n/a
Volume 563,842
Average Volume 281,458
Open 6.35
Previous Close 6.50
Day's Range 5.47 - 6.35
52-Week Range 2.12 - 8.43
Beta 0.41
RSI 60.67
Earnings Date Feb 13, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 2
Stock Exchange Nasdaq Stockholm
Ticker Symbol ELIC
Full Company Profile

Financial Performance

In 2025, Elicera Therapeutics AB's revenue was 10.86 million, an increase of 52.28% compared to the previous year's 7.13 million. Losses were -17.41 million, 8.05% more than in 2024.

Financial Statements

News

There is no news available yet.